Anzeige
Erschienen in:
16.03.2023
Current Screening and Management Strategies for Dysplasia in IBD
Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 2/2023
Einloggen, um Zugang zu erhaltenAbstract
Purpose of review
An association between development of colorectal cancer (CRC) and inflammatory bowel disease (IBD) has long been established. Significant advances in the detection and management of dysplastic lesions have occurred in recent years. The purpose of our review is to summarize available literature and recommendations on screening and management of dysplasia in IBD.
Recent findings
The major advancement of endoscopic techniques and the almost standard use of high definition (HD) colonoscopes allows for better identification of small and subtle dysplastic lesions. In addition to dye chromoendoscopy (DCE) as a modality for dysplasia surveillance, recent studies suggest that virtual chromoendoscopy (VCE) and high definition-white light endoscopy (HD-WLE) are suitable options for surveillance. Additionally, management of dysplastic lesions is shifting towards endoscopic resection if technically feasible with ongoing endoscopic surveillance over proctocolectomy.
Summary
Patients with IBD are known to have an increased risk of dysplasia and CRC. The goal of surveillance colonoscopy is early detection and management of dysplastic lesions. DCE, VCE, and HD-WLE are considered suitable options for dysplasia surveillance by experienced endoscopists. Endoscopic resection with continued surveillance is the most common strategy used for management of dysplastic lesions.